Inicio / Oncología / Abstracts de oncología / Technetium-99m- or Cy7-Labele…

Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma

5 / 5 (1 votos)
Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma

Oncology: International Journal of Cancer Research and Treatment
April 2017, Vol.92,  No. 4

Camacho X.a, Machado C.L.e, García M.F.a, Gambini J.P.b, Banchero A.a, Fernández M.a, Oddone N.c, Bertolini Zanatta D.f, Rosal C.f, Buchpiguel C.A.e, Chammas R.g, Riva E.d, Cabral P.a

Abstract

Introduction: 

Rituximab was the first monoclonal antibody approved for the treatment of B-cell non-Hodgkin lymphoma (NHL) expressing CD20 antigen. This antibody has also the potential to be used as a specific fluorescent and radiolabel agent for targeting NHL.

Objective:

To radiolabel rituximab with technetium-99m (99mTc) or Cy7 and evaluate both probes as potential imaging agents for NHL.

Methods: 

Rituximab was derivatized with the trifluoroacetyl hydrazino protected form of succinimidyl ester of HYNIC and radiolabeled with 99mTc. Radiochemical stability and in vitro cell assays were evaluated. Biodistribution and single-photon emission computed tomography/computed tomography (SPECT/CT) were performed. Raji cells were transfected with luciferase for bioluminescent NHL imaging up to 21 days. Rituximab was labeled with Cy7 for in vivo noninvasive fluorescence imaging up to 96 h

SEGUIR LEYENDO

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.